GR3005447T3 - - Google Patents

Info

Publication number
GR3005447T3
GR3005447T3 GR920400780T GR920400780T GR3005447T3 GR 3005447 T3 GR3005447 T3 GR 3005447T3 GR 920400780 T GR920400780 T GR 920400780T GR 920400780 T GR920400780 T GR 920400780T GR 3005447 T3 GR3005447 T3 GR 3005447T3
Authority
GR
Greece
Prior art keywords
galanthamine
alzheimer
disease
treated
Prior art date
Application number
GR920400780T
Other languages
Greek (el)
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25227312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR3005447(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GR3005447T3 publication Critical patent/GR3005447T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GR920400780T 1986-01-15 1992-08-20 GR3005447T3 (en:Method)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/819,141 US4663318A (en) 1986-01-15 1986-01-15 Method of treating Alzheimer's disease

Publications (1)

Publication Number Publication Date
GR3005447T3 true GR3005447T3 (en:Method) 1993-05-24

Family

ID=25227312

Family Applications (2)

Application Number Title Priority Date Filing Date
GR88300077T GR880300077T1 (en) 1986-01-15 1988-10-21 Galanthamine or analogues thereof for treating alzheimer's disease
GR920400780T GR3005447T3 (en:Method) 1986-01-15 1992-08-20

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GR88300077T GR880300077T1 (en) 1986-01-15 1988-10-21 Galanthamine or analogues thereof for treating alzheimer's disease

Country Status (10)

Country Link
US (1) US4663318A (en:Method)
EP (1) EP0236684B1 (en:Method)
JP (1) JPH08778B2 (en:Method)
AT (1) ATE76294T1 (en:Method)
AU (1) AU593051B2 (en:Method)
DE (3) DE236684T1 (en:Method)
ES (1) ES2000428T3 (en:Method)
GR (2) GR880300077T1 (en:Method)
LU (1) LU90710I2 (en:Method)
NL (1) NL300140I2 (en:Method)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150354A (en) * 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
KR100195399B1 (ko) * 1987-05-04 1999-06-15 보니데이비스 알쯔하이머 병 치료용 의약
IT1222395B (it) * 1987-07-30 1990-09-05 Pierrel Spa Composizione farmaceutica per somministrazione intranasale comprendente l'ormone ghrh,un agonista colinergico e/o un sale biliare
US4897388A (en) * 1988-12-20 1990-01-30 Geriatric Research Institute, Inc. Method of treating Alzheimer's disease
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
US5519017A (en) * 1990-03-29 1996-05-21 Lts Lohmann Therapie-Systeme Gmbh + Co. Kg Pharmaceutic formulation for the treatment of alcoholism
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
JP3291730B2 (ja) * 1991-05-14 2002-06-10 エルニア スノラソン 疲労症候群の治療
US5177070A (en) * 1991-11-15 1993-01-05 Ciba-Geigy Corporation Method of treating physiologic male erectile impotence
DE4301782C1 (de) * 1993-01-23 1994-08-25 Lohmann Therapie Syst Lts Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit
DE4301783C1 (de) * 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
US6323196B1 (en) * 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6323195B1 (en) * 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6316439B1 (en) 1993-10-15 2001-11-13 Aventis Pharamaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
KR100352212B1 (ko) * 1994-10-21 2003-04-18 자노케미아 파마조이티카 악티엔게젤샤프트 4a,5,9,10,11,12-헥사히드로-6H-벤조푸로[3a,3,2-ef][2]벤즈아제핀유도체의제조방법
US6407229B1 (en) 1994-10-21 2002-06-18 Sanochemia Pharmazeutika Ag Processes for the preparation of derivatives of 4a,5,9,10,11,12-hexahydro-6H-benzofuro-[3a,3,2-ef][2] benzazapine
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
GB9514821D0 (en) * 1995-07-19 1995-09-20 Sod Conseils Rech Applic Galanthamine derivatives
AT402691B (de) * 1996-01-26 1997-07-25 Sanochemia Ltd Verwendung von galanthamin zum herstellen von arzneimitteln zur behandlung von trisomie 21 oder verwandter trisomie-syndrome
AT403803B (de) * 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
AU2004242546B2 (en) * 1998-11-23 2008-05-15 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
US7939522B1 (en) 1998-11-23 2011-05-10 Bonnie M Davis Dosage formulations for acetylcholinesterase inhibitors
HRP20010463B1 (hr) * 1998-12-24 2011-02-28 Janssen Pharmaceutica N.V. Smjesa s kontroliranim otpuštanjem koja sadrži galantamin
US20050063998A1 (en) * 1999-10-26 2005-03-24 Francois Marc Karel Jozef Oral solution containing galantamine and a sweetening agent
ATE297737T1 (de) * 2000-01-28 2005-07-15 Tricia Grose Zusatz aus kräutern zur behandlung von kognitiven störungen aufgrund von östrogenverlust
US6426097B2 (en) 2000-01-28 2002-07-30 Herbaceuticals Inc. Herbal supplement for cognitive related impairment due to estrogen loss
PT1181294E (pt) 2000-03-31 2004-07-30 Sanochemia Pharmazeutika Ag Novos derivados e analogos da galantamina
CA2310990A1 (en) 2000-04-03 2000-10-09 Michael Pontecorvo A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease
CA2310926C (en) 2000-04-03 2002-10-15 Janssen Pharmaceutica N.V. A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
AU2001257022B2 (en) * 2000-04-13 2005-02-03 Mayo Foundation For Medical Education And Research Abeta 42 lowering agents
JP4721386B2 (ja) * 2001-07-10 2011-07-13 第一三共株式会社 新規ガランタミン類縁体
US20030162770A1 (en) * 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
EP1514542B1 (en) 2002-06-14 2012-02-22 Toyama Chemical Co., Ltd. Medicinal composition comprising Tacrine or Donepezil for improving brain function.
US20040067934A1 (en) * 2002-10-03 2004-04-08 Parys Wim Louis Julien Use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
AU2003274353B2 (en) * 2002-10-24 2007-04-05 Merz Pharma Gmbh & Co. Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
US20040097484A1 (en) * 2002-11-14 2004-05-20 Marc Cantillion Once a day galantamine pharmaceutical compositions and methods of use
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
WO2004108085A2 (en) * 2003-05-30 2004-12-16 Microbia, Inc. Methods for the protection of memory and cognition
EP1651195A4 (en) * 2003-07-11 2007-10-03 Myriad Genetics Inc PHARMACEUTICAL PROCESSES, DOSIERSCHEMATA AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER DISEASE
US20050048543A1 (en) * 2003-07-11 2005-03-03 Jeroen Aerssens CHRNA2 genetic markers associated with galantamine response
PL1651234T3 (pl) * 2003-07-25 2008-02-29 Hoffmann La Roche Kompozycja antagonisty mGluR2 i inhibitora AChE do leczenia ostrych i/lub przewlekłych zaburzeń neurologicznych
WO2005042762A2 (en) * 2003-10-28 2005-05-12 Genaissance Pharmaceuticals, Inc. Lrpap1 genetic markers associated with galantamine response
BG65658B1 (bg) * 2003-11-13 2009-05-29 "Софарма" Ад Комбиниран лекарствен продукт на основата на галантамин
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
US7250258B2 (en) * 2003-12-15 2007-07-31 Pgxhealth Llc CDK5 genetic markers associated with galantamine response
US20050191349A1 (en) * 2003-12-31 2005-09-01 Garth Boehm Galantamine formulations
US20050142193A1 (en) * 2003-12-31 2005-06-30 Lijuan Tang Galantamine formulations
EP1718291A1 (en) * 2004-02-19 2006-11-08 Novartis AG Use of cholinesterase inhibitors for treating vascular depression
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
MXPA06012165A (es) * 2004-04-29 2007-01-17 Keystone Retaining Wall System Chapas para muros, muros de contencion y similares.
WO2005112946A1 (en) * 2004-05-14 2005-12-01 The Johns Hopkins University Method for improving cognitive function by co-administration of a gabab receptor antagonist and an acetylcholinesterase inhibitor
EP1779867A4 (en) * 2004-07-01 2009-12-02 Eisai R&D Man Co Ltd MEANS FOR PROMOTING NERVE REVENERATION
CA2618985A1 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
EP1819681B1 (en) * 2004-11-23 2009-08-12 Warner-Lambert Company LLC 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia
EP1827468B1 (en) * 2004-12-23 2012-08-22 Curaxis Pharmaceutical Corporation Acetylcholinesterase Inhibitors and leuprolide acetate for the treatment of Alzheimer's disease
MX2007012374A (es) * 2005-04-06 2008-02-22 Adamas Pharmaceuticals Inc Metodos y composiciones para el tratamiento de condiciones relacionadas con cns.
US20080188510A1 (en) * 2005-05-23 2008-08-07 Eisai R & D Management Co., Ltd. Novel methods using zonisamide
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
WO2007014124A2 (en) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. High drug load formulations and dosage forms
EP2046119A2 (en) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Treatment of psychiatric disorders
ATE549021T1 (de) 2006-10-27 2012-03-15 Medivation Neurology Inc Kombinationstherapien zur behandlung von morbus alzheimer mit dimebon und donepezil
US20110201597A1 (en) 2008-03-27 2011-08-18 Chase Thomas N Method and composition for treating alzheimer-type dementia
PL2271218T3 (pl) 2008-03-27 2017-10-31 Chase Pharmaceuticals Corp Zastosowanie i kompozycja do leczenie otępienia
IN2012DN02122A (en:Method) 2009-09-18 2015-08-21 Chase Pharmaceuticals Corp
EP2503996A2 (en) 2009-11-26 2012-10-03 USV Limited Controlled release pharmaceutical compositions of galantamine
CN102905532A (zh) 2010-02-09 2013-01-30 约翰斯.霍普金斯大学 用于改善认知功能的方法和组合物
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
FR2962335B1 (fr) 2010-07-12 2013-01-18 Cll Pharma Utilisation du nonapeptide pat dans le traitement et la prevention des maladies neurodegeneratives
HK1210947A1 (en) 2012-09-05 2016-05-13 Chase Pharmaceuticals Corporation Anticholinergic neuroprotective composition and methods
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA
BG66818B1 (bg) 2013-03-07 2019-01-31 Berbee Beheer B. V. Състав на екстракт от hippeastrum papilio за производство на лекарствени средства и хранителни добавки
EP3827820A1 (en) 2013-03-15 2021-06-02 The Johns Hopkins University Brivaracetam for improving cognitive function
HK1218623A1 (zh) 2013-03-15 2017-03-03 艾吉因生物股份有限公司 用於改善認知功能的方法和組合物
TW201540301A (zh) 2013-08-16 2015-11-01 Takeda Gmbh 以ｐｄｅ４抑制劑治療認知損傷
CA2986598C (en) 2015-05-22 2023-09-26 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam

Also Published As

Publication number Publication date
EP0236684B1 (en) 1992-05-20
ES2000428T9 (es) 2013-08-14
EP0236684A2 (en) 1987-09-16
ATE76294T1 (de) 1992-06-15
DE10199020I1 (de) 2001-05-23
NL300140I2 (nl) 2004-04-01
DE236684T1 (de) 1988-04-28
AU6760987A (en) 1987-07-16
JPH08778B2 (ja) 1996-01-10
AU593051B2 (en) 1990-02-01
ES2000428T3 (es) 1993-10-01
GR880300077T1 (en) 1988-10-21
LU90710I2 (fr) 2001-03-05
ES2000428A4 (es) 1988-03-01
DE3779149D1 (de) 1992-06-25
US4663318A (en) 1987-05-05
JPS62215527A (ja) 1987-09-22
EP0236684A3 (en) 1988-12-14
NL300140I1 (nl) 2004-02-02
DE10199020I2 (de) 2004-05-06

Similar Documents

Publication Publication Date Title
GR3005447T3 (en:Method)
EP0244850A3 (en) Shredder
EP0558100A3 (en) Bipolar transistor
GB8725631D0 (en) Bipolar transistor
GB9026055D0 (en) Bearing treatment
GB8621869D0 (en) Treatment
PT84294A (en) Novel treatment
PH22837A (en) Indolophenanthridines
KR960003369B1 (en) Transistor arrangement
ZA879505B (en) Flyslag treatment
AU97894S (en) Shredder
ZA87481B (en) Fabrik treatment agents
AU97706S (en) Shredder
GB8610314D0 (en) Bipolar transistor
IT8821688A0 (it) Macinacaffe'.
GB8617623D0 (en) Treatment
GB8615669D0 (en) Treatment
CS551586A1 (en) Sposob vyroby bimetalickych suciastok s minialnou medzou pevnosti v tahu oceloveho podkladu 1800 mpa
GB8914964D0 (en) Novel treatment i
GB8627070D0 (en) Treatment
GB8601120D0 (en) Treatment
GB8629641D0 (en) Treatment
GB8619487D0 (en) Treatment
GB8628935D0 (en) Treatment
GB8627071D0 (en) Treatment